Regeneron Pharmaceuticals (REGN) Aperçu de l'action
Regeneron Pharmaceuticals, Inc. découvre, invente, développe, fabrique et commercialise des médicaments pour traiter diverses maladies dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 6/6 |
| Croissance future | 1/6 |
| Performances passées | 1/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
REGN ont passé avec succès nos contrôles de risques.
REGN Community Fair Values
Create NarrativeSee what 163 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Regeneron Pharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$664.52 |
| Plus haut sur 52 semaines | US$821.11 |
| Plus bas sur 52 semaines | US$541.00 |
| Bêta | 0.24 |
| Variation sur 1 mois | 8.56% |
| Variation sur 3 mois | -10.98% |
| Variation sur 1 an | 17.05% |
| Variation sur 3 ans | -7.52% |
| Variation sur 5 ans | 13.94% |
| Évolution depuis l'introduction en bourse | 3,045.66% |
Nouvelles et mises à jour récentes
Recent updates
Mise à jour du récit • Jun 24
REGN: Core Immunology Cash Flows Will Support Pipeline And Oncology Upside
Regeneron Pharmaceuticals' updated analyst fair value has shifted lower by about $42 to $833, as analysts factor in reduced expectations for the fianlimab program after recent Phase 3 trial disappointments, softer modeled revenue growth and margins, and a lower assumed future P/E multiple. Analyst Commentary Recent research on Regeneron Pharmaceuticals centers on the impact of fianlimab trial results, competitive pressures around key franchises, and how these factors feed into earnings forecasts and valuation multiples.
Mise à jour du récit • Jun 09
REGN: Future Re Rating Will Hinge On Reset Oncology Pipeline Optionality
Analysts have reduced their fair value estimate for Regeneron Pharmaceuticals to $1,000 from $1,030 after a series of lower Street price targets followed the company’s disappointing Phase 3 fianlimab and LAG-3 melanoma trial results. Analyst Commentary Street research following the fianlimab and LAG-3 melanoma trial update has been active, with most recent moves skewed toward lower fair value assumptions and, in some cases, rating downgrades.
Mise à jour du récit • May 26
REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects
Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street. Analyst Commentary Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades.Seeking Alpha • May 18
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking AlphaMise à jour du récit • May 03
REGN: Expanding Immunology And Gene Therapy Will Support Future Upside
Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.Mise à jour du récit • Apr 19
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.Mise à jour du récit • Apr 04
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.Mise à jour du récit • Mar 21
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.Mise à jour du récit • Mar 07
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.Mise à jour du récit • Feb 21
REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.Mise à jour du récit • Feb 06
REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.Mise à jour du récit • Jan 23
REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.Mise à jour du récit • Jan 09
REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.Mise à jour du récit • Dec 25
REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.Mise à jour du récit • Dec 11
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.Mise à jour du récit • Nov 27
REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.Article d’analyse • Nov 19
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...Mise à jour du récit • Nov 12
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.Article d’analyse • Nov 09
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...Mise à jour du récit • Oct 28
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.Mise à jour du récit • Sep 18
Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.Rendement pour les actionnaires
| REGN | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 1.6% | -2.3% | 0.8% |
| 1Y | 17.0% | 35.8% | 20.6% |
Rendement vs Industrie: REGN a sous-performé le secteur US Biotechs qui a rapporté 35.8 % au cours de l'année écoulée.
Rendement vs marché: REGN a sous-performé le marché US qui a rapporté 20.6 % au cours de l'année écoulée.
Volatilité des prix
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: REGN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de REGN ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1988 | 15,343 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. découvre, invente, développe, fabrique et commercialise des médicaments destinés au traitement de diverses maladies à l'échelle mondiale. La société développe des produits candidats pour le traitement des maladies oculaires, allergiques et inflammatoires, cardiovasculaires, métaboliques, neurologiques, infectieuses et rares, ainsi que du cancer et des troubles hématologiques. Elle propose également les injections d'EYLEA pour la dégénérescence maculaire liée à l'âge de type humide et l'œdème maculaire diabétique ; la néovascularisation choroïdienne myopique ; la rétinopathie diabétique ; le glaucome néovasculaire ; la rétinopathie du prématuré ; l'injection de Dupixent pour traiter la dermatite atopique et l'asthme ; l'injection de Libtayo pour le carcinome épidermoïde cutané métastatique ou localement avancé ; l'injection de Praluent pour traiter l'hypercholestérolémie familiale hétérozygote (HoFH) ; et la solution de Kevzara pour la polyarthrite rhumatoïde.
Regeneron Pharmaceuticals, Inc. Résumé des fondamentaux
| REGN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$67.61b |
| Bénéfices(TTM) | US$4.42b |
| Recettes(TTM) | US$14.92b |
15.3x
Ratio P/E4.5x
Ratio P/SLe site REGN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| REGN compte de résultat (TTM) | |
|---|---|
| Recettes | US$14.92b |
| Coût des recettes | US$8.37b |
| Marge brute | US$6.55b |
| Autres dépenses | US$2.12b |
| Les revenus | US$4.42b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 30, 2026
| Résultat par action (EPS) | 43.48 |
| Marge brute | 43.89% |
| Marge bénéficiaire nette | 29.65% |
| Ratio dettes/capitaux propres | 6.3% |
Quelles ont été les performances à long terme de REGN?
Voir les performances historiques et les comparaisonsDividendes
0.6%
Rendement actuel des dividendes8%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/12 01:28 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Regeneron Pharmaceuticals, Inc. est couverte par 53 analystes. 27 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |